tremelimumab plus MEDI4736
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Mesothelioma
Conditions
Pleural Mesothelioma, Peritoneal Mesothelioma
Trial Timeline
Oct 1, 2015 → Mar 1, 2018
NCT ID
NCT02588131About tremelimumab plus MEDI4736
tremelimumab plus MEDI4736 is a phase 2 stage product being developed by AstraZeneca for Pleural Mesothelioma. The current trial status is unknown. This product is registered under clinical trial identifier NCT02588131. Target conditions include Pleural Mesothelioma, Peritoneal Mesothelioma.
What happened to similar drugs?
0 of 4 similar drugs in Pleural Mesothelioma were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02588131 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Pleural Mesothelioma